scholarly journals Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy

2019 ◽  
Vol 25 ◽  
pp. 9855-9863
Author(s):  
Tomoyoshi Shibuya ◽  
Kei Nomura ◽  
Koki Okahara ◽  
Keiichi Haga ◽  
Osamu Nomura ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Biological Therapy ◽  
Inadequate Response ◽  
Budesonide Foam

scholarly journals AB0237 INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH RITUXIMAB AND ANTI-TNF INHIBITOR

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1144.2-1144
Author(s):  
N. Zehraoui ◽  
R. Benaziez.Boutaleb ◽  
H. Hafirassou ◽  
F. Mechid ◽  
N. Bahaz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Best Practice ◽  
Biological Therapy ◽  
Patient Characteristics ◽  
Inadequate Response ◽  
Tnf Inhibitor ◽  
Clinical Rheumatology ◽  
Number Of Patients ◽  
Serious Infections ◽  
Comparative Risk

Background:Biological therapies have significantly improved the management of rheumatoid arthritis (RA). These molecules are very effective, but are known for their specific risks, especially infectious. It depends on several factors including the type of molecule used.Objectives:The objective of our study is to compare the rate of infection in RA patients treated with rituximab and anti-TNFα.Methods:Prospective, observational, monocentric study. Were included RA patients (ACR / EULAR 2010 criteria) treated with rituximab and anti-TNFα (adalimumab, infliximab and Etanercept) after inadequate response to DMARDs.Demographic characteristics, comorbidities, association with methotrexate and corticosteroids were collected and compared for each group.The number, type and severity of the infections in both cases were noted.SPSS (Statistical Package for Social Science) was used for data analysis.Results:40 RA patients treated with rituximab and 31 patients who received anti-TNFα were included.Patient characteristics and Comparison of rate of infection in RA patients between the two groups are summarized in Table 1Table 1.ParametersRituximabAnti-TNFαpNumber of patients4031Average age (years)56,2846,060,01Sexratio0,140,110,7Average duration of evolution (years)15,8313,740,3Patients under corticosteroid (%)97,587,10,08Average corticosteroid dose6,415,480,3patients under methotrexate (%)37,545,20,5Diabetes (%)2016,10,7Patients with infection (%)32,551,60,1Number of infections18240,4Number of serious infections500,04Conclusion:The rate of infections in patients with RA treated with rituximab or anti-TNF was similar. However, the infections observed were more serious in patients with RA treated with rituximabReferences:[1]Fabiola Atzeni MD PhD and al. Infections and Biological Therapy in Patients with Rheumatic Diseases. IMAJ . VOL 18. march-APRIL 2016.[2]Huifeng Yun and al. Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. ARTHRITIS & RHEUMATOLOGY. Vol. 68, No. 1, January 2016, pp 56–66.[3]Manjari Lahiri and al. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Practice & Research Clinical Rheumatology (2015) 1-16.Disclosure of Interests:None declared

scholarly journals PATIENTS WITH INFLAMMATORY BOWEL DISEASE PERSPECTIVE ON COVID-19 AND HEALTH CARE SERVICE DURING THE PANDEMIC

2021 ◽  
Vol 27 (Supplement_1) ◽  
pp. S50-S51
Author(s):  
Randi Opheim ◽  
Kristian Moum ◽  
Bjørn Moum
Keyword(s):  
Ulcerative Colitis ◽  
Health Care ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Medical Treatment ◽  
Biological Therapy ◽  
Care Service ◽  
Health Care Service ◽  
Inflammatory Bowel

Abstract Background Patients with inflammatory bowel diseases (IBD) have experienced changes to the routine management of their conditions during the coronavirus disease (COVID-19) pandemic. The disease as well IBD treatment frequently require immunosuppressant medications, which could increase their risk of infection. The aim of this study was to determine patients’ experience of the health care service, including the restrictions of hospitals visits made in Norway from Mars 12th 2020. Method From June 18 to September 18 2020, all patients at the IBD outpatient clinic at Oslo University Hospital in Norway on biological therapy or other immunosuppressant’s were included. A questionnaire including patients concerns regarding their disease, medical therapy and COVID-19, as well as their health care service needs in follow-up during the COVID-19 pandemic. Results Altogether 506 IBD patients answered a paper-based questionnaire. The mean age was 40.78 (SD 14.71), 289/506 (57%) men, ulcerative colitis 199/506 (39%), Crohn’s disease 307/506 (61%). Sixty-three patients (12.5%) used biological therapy in combination with azathioprine or steroids. Ninety-one (18.2%) were in obligated quarantine with negative test. Five patients (4.9%) tested positive to SARS- CoV-2 of the 98 patients tested, (1.0% of the total sample). One third of the IBD patients perceived they had increased risk for being infected by SARS- CoV-2 because of the immunosuppressive drugs they used. Nonetheless, 496/506 (98.6%) of the patients adhered to continuing their medication. One-hundred and sixty-one (32.3%) voluntarily isolated, and 21/506 (4.2%) was in sick leave being afraid of being infected. Furthermore, 20/506 (4.0%) cancelled their consultation because they were afraid of being infected from SARS- CoV-2 at the hospital. The hospital changed physical consultation to telephone consultation for 75/506 (15.0%) of the patients. Thirty-eight patients (7.6%) reported that they were afraid of going to the hospital because of restrictions due to the COVID-19 pandemic, and 18/506 (3.6%) did not feel safe when at hospital. Approximately half of the IBD patients (219/506) were satisfied with the information provided by physician about medical treatment for IBD and Covid-19 while 398/506 (77.3%) were satisfied with the information from health-care providers about restrictions due to COVID-19. There were no statistical differences between Crohn’s disease and ulcerative colitis. Conclusion IBD patients on biological treatment and immunosuppressives took precautions because of fear of being infected with SARS- CoV-2. At the same time, they adhere to medical treatment regimens and follow-up at the hospital. Most patients were satisfied with the information they received from physicians and other health-care workers. One percent tested positive to SARS-CoV-2.

IDENTIFYING INADEQUATE RESPONSE AMONG ULCERATIVE COLITIS PATIENTS ON AN ADVANCED THERAPY IN A REAL-WORLD ADMINISTRATIVE CLAIMS DATABASE

2021 ◽  
Vol 160 (3) ◽  
pp. S26-S27
Author(s):  
April Naegeli ◽  
Theresa Hunter ◽  
Michael Grabner ◽  
Keith Isenberg ◽  
Mingyang Shan ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Real World ◽  
Administrative Claims ◽  
Inadequate Response ◽  
Claims Database ◽  
Advanced Therapy

scholarly journals FACTORS ASSOCIATED WITH PATIENT´S PREFERENCE IN CHOOSING THEIR THERAPY FOR INFLAMMATORY BOWEL DISEASE IN BRAZIL

2020 ◽  
Vol 57 (4) ◽  
pp. 491-497
Author(s):  
Adhan Amenomori WU ◽  
Jaqueline Ribeiro de BARROS ◽  
Madhoor RAMDEEN ◽  
Julio Pinheiro BAIMA ◽  
Rogerio SAAD-HOSSNE ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Therapy ◽  
Oral Route ◽  
New Drugs ◽  
Cross Sectional ◽  
Mode Of Administration ◽  
Mode Of Application ◽  
Inflammatory Bowel

BACKGROUND: Biological therapy and new drugs have revolutionized the treatment of inflammatory bowel disease. Ideally, the choice of medication should be a shared decision with the patient, aiming at greater satisfaction, compliance, and consequently, favorable clinical outcome. OBJECTIVE: This study aims to evaluate patient’s preferences in the choice of their therapy and the factors that influence this choice. METHODS: This cross-sectional study enrolled 101 outpatients with Crohn’s disease or ulcerative colitis. The inclusion criteria were age ≥18 years and no previous exposure to biological therapy. Patients’ preferences were assessed through questions that addressed the preferred mode of administration (oral, subcutaneous, or intravenous) and the factors that determined the choice of medication (efficacy, medical indication, fear of medication, convenience, mode of application, and personal doctors’ indication). RESULTS: The mean age was 43.6±13.5 years, 75.3% were female, and 81.2% were cases of ulcerative colitis. Regarding the mode of administration, the majority of patients preferred oral (87.1%), followed by intravenous (6.93%) and subcutaneous (5.94%) medications. The reasons were “I prefer to take it at home” (42.57%), “I have more freedom” (36.63%), “I don’t like self-application” (29.70%), and “I believe it works better” (19.80%). Younger patients and patients in clinical disease activity preferred intravenous mode compared to the oral route (P<0.05). Doctor’s opinion (98%) was an important factor associated with the medication choice. CONCLUSION: Oral route was the preferred mode of administration and most patients took their physician’s opinion into account in their choice of medication.

scholarly journals P321 The one-year efficacy of infliximab does not depend on the timing of biological therapy in ulcerative colitis

2014 ◽  
Vol 8 ◽  
pp. S198-S199
Author(s):  
T. Molnar ◽  
A. Bálint ◽  
T. Nyári ◽  
K. Farkas ◽  
R. Bor ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Biological Therapy ◽  
One Year ◽  
The One

EFFECTS OF BIOLOGICAL THERAPY ON QUALITY OF LIFE AND PSYCHOEMOTIONAL STATUS OF PATIENTS WITH ULCERATIVE COLITIS

2021 ◽  
Vol 74 (10) ◽  
pp. 2610-2613
Author(s):  
Antonina V. Varvarynets
Keyword(s):  
Quality Of Life ◽  
Ulcerative Colitis ◽  
Biological Therapy ◽  
Old Patients ◽  
Group Iii ◽  
Group I ◽  
Sf 36 ◽  
Nonspecific Ulcerative Colitis ◽  
Social Introversion

The aim: To compare the effects of tofacitinib, adalimumab and budesonide on the quality of life and psychoemotional status of patients with moderate UC. Materials and methods: The study included 104 patients with moderately severe UC aged between 18 and 75 years old. Patients were divided into 3 groups. Group I consisted of patients with UC treated with budesonide 9 mg 1 g / d (BUD; n = 34). Group II – of patients receiving adalimumab at an initial dose of 160 mg and 80 mg at week 2, followed by maintenance dose of 40 mg weekly (ADA; n = 38) and group III, who received tofacitinib 10 mg 2p / d (TOF; n = 32). Evaluation of quality of life and psycho-emotional status of patients was performed using IBDQ, SF-36 and MMRI questionnaires. Results: According to the IBDQ-questionnaire, all groups after treatment had a statistically significant increase in their results: BUD (from 146,44 ± 2,23 to 151,36 ± 2,40), ADA (from 144,28 ± 3,10 to 172,36 ± 3,12), TOF (from 149,22 ± 2, 86 to 184.36 ± 2.88), respectively, p <0.05. Also, after treatment statistically significant changes were seen in patients of all groups in regards to the psychological and physical components of the SF-36 scale. Analysis of the personality profile using MMRI of all groups of patients showed a change in scales 2 (depression), 3 (hysteria), 5 (tenderness-femininity), 6 (paranoia) and 0 (social introversion), which significantly improved in the ADA and TOF groups. Conclusions: Tofacitinib and adalimumab in patients with nonspecific ulcerative colitis of moderate severity had a better effect on quality of life and psychoemotional status compared with budesonide treatment.

Sign in / Sign up

Export Citation Format

Share Document